Sponsored by
Very exciting news! DB107 is the new name for a previously tested 2-drug combination (Toca 511 + Toca FC). The Musella Foundation was an early supporter of the treatment via grants, back when the drugs were owned by a company called Tocagen. Early trials did well. The large Phase 3 trial failed, but there was a small subset of very successful responders. At first, nobody knew why only some patients benefited, but the company that now owns the drugs (Denovo) discovered a new biomarker they believe accounts for the favorable response. Based on this discovery, new trials will be launched to confirm the treatment helps patients who have the relevant 'DGM7' biomarker. This large grant will help fund the trials, and we hope to see enrollment opening soon!